Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility
- PMID: 9476508
- DOI: 10.1111/j.1439-0507.1997.tb00230.x
Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility
Abstract
Fluconazole shows good penetration into the tissues and body fluids examined and a rapid equilibrium is achieved between the concentrations in the various compartments. The pharmacokinetics of fluconazole after intravenous or oral administration are proportional to the dose. This finding, together with the slow elimination of the triazole (t1/2 30 h), makes it easier to forecast the therapeutically effective dosage. Measurements of fluconazole concentration in blood can be used to predict levels in some tissues (lung, brain, gynaecological samples), body fluids (sputum, saliva, vaginal secretions) or exudates. Concentrations in cerebrospinal fluid and vitreous humour of the eye reach approximately 80% of the levels found in blood. A very high proportion of fluconazole is excreted unchanged in the urine, where concentrations of the drug are 10-20-fold higher than in blood. Whilst this pharmacokinetic profile is valuable in the treatment of fungal infections of the urinary tract, it also means that the dosage may need to be decreased in patients with renal impairment. The susceptibility of fungi to fluconazole in vitro and in vivo correlates well with the concentrations of the drug measured in various compartments of the body.
Similar articles
-
[Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility of yeasts].Mycoses. 1996;39 Suppl 2:51-7. doi: 10.1111/j.1439-0507.1996.tb00529.x. Mycoses. 1996. PMID: 9198746 Review. German.
-
Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.Clin Pharmacokinet. 1997 Jul;33(1):52-77. doi: 10.2165/00003088-199733010-00005. Clin Pharmacokinet. 1997. PMID: 9250423
-
Fluconazole: optimized antifungal therapy based on pharmacokinetics.Mycoses. 2002;45 Suppl 3:39-41. doi: 10.1111/j.1439-0507.2002.tb04768.x. Mycoses. 2002. PMID: 12690970 Review.
-
[Plasma and tissue concentrations of fluconazole: discussion of the breakpoint problem].Mycoses. 1996;39 Suppl 2:58-65. doi: 10.1111/j.1439-0507.1996.tb00530.x. Mycoses. 1996. PMID: 9198747 Review. German.
-
High-dose fluconazole therapy in patients with severe fungal infections.Eur J Clin Microbiol Infect Dis. 1999 Mar;18(3):165-74. doi: 10.1007/s100960050252. Eur J Clin Microbiol Infect Dis. 1999. PMID: 10357048 Review. No abstract available.
Cited by
-
Treatment for recurrent vulvovaginal candidiasis (thrush).Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD009151. doi: 10.1002/14651858.CD009151.pub2. Cochrane Database Syst Rev. 2022. PMID: 35005777 Free PMC article.
-
Pediatric antifungal agents.Curr Opin Infect Dis. 2009 Dec;22(6):553-8. doi: 10.1097/QCO.0b013e3283321ccc. Curr Opin Infect Dis. 2009. PMID: 19741525 Free PMC article. Review.
-
Antifungal therapy in children: an update.Eur J Pediatr. 2013 Apr;172(4):437-46. doi: 10.1007/s00431-012-1758-9. Epub 2012 Jun 1. Eur J Pediatr. 2013. PMID: 22652706
-
Determination of pollutants, antibiotics, and drugs in surface water in Italy as required by the third EU Water Framework Directive Watch List: method development, validation, and assessment.Environ Sci Pollut Res Int. 2024 Feb;31(10):14791-14803. doi: 10.1007/s11356-024-32025-6. Epub 2024 Jan 27. Environ Sci Pollut Res Int. 2024. PMID: 38280169 Free PMC article.
-
Tissue penetration of antifungal agents.Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13. Clin Microbiol Rev. 2014. PMID: 24396137 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical